Lyra Therapeutics Inc
NASDAQ:LYRA

Watchlist Manager
Lyra Therapeutics Inc Logo
Lyra Therapeutics Inc
NASDAQ:LYRA
Watchlist
Price: 8.55 USD 0.23% Market Closed
Market Cap: 13.7m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
+7%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

LYRA Price Targets Summary
Lyra Therapeutics Inc

Wall Street analysts forecast LYRA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LYRA is 23.46 USD with a low forecast of 16.16 USD and a high forecast of 31.5 USD.

LYRA Lowest Forecast
Wall Street Target
16.16 USD
89% Upside
LYRA Average Forecast
Wall Street Target
23.46 USD
174% Upside
LYRA Highest Forecast
Wall Street Target
31.5 USD
268% Upside
Lowest
Price Target
16.16 USD
89% Upside
Average
Price Target
23.46 USD
174% Upside
Highest
Price Target
31.5 USD
268% Upside
Lyra Therapeutics Inc Competitors:
Price Targets
UCB
Ucb SA
24% Upside
DRREDDY
Dr Reddy's Laboratories Ltd
4% Upside
A
ABBOTINDIA
Abbott India Ltd
6% Upside
600216
Zhejiang Medicine Co Ltd
12% Upside
UCB
Ucb SA
24% Upside
DRREDDY
Dr Reddy's Laboratories Ltd
4% Upside
A
ABBOTINDIA
Abbott India Ltd
6% Upside
600216
Zhejiang Medicine Co Ltd
12% Upside
H
200670
Humedix Co Ltd
5% Upside
PFE
Pfizer Inc
19% Upside

Revenue
Forecast

Revenue Estimate
Lyra Therapeutics Inc

The compound annual growth rate of Lyra Therapeutics Inc's revenue for the next 3 years is 115%.

N/A
Past Growth
115%
Estimated Growth
Estimates Accuracy
-42%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Lyra Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Lyra Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-54%
Average Miss
What are analyst estimates?

See Also

Summary
LYRA intrinsic value, competitors valuation, and company profile.
DCF Valuation
LYRA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LYRA stock valuation using valuation multiples.
Wall Street Estimates
LYRA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LYRA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LYRA's stock price target?
Price Target
23.46 USD

According to Wall Street analysts, the average 1-year price target for LYRA is 23.46 USD with a low forecast of 16.16 USD and a high forecast of 31.5 USD.

What is Lyra Therapeutics Inc's Revenue forecast?
Projected CAGR
115%

The compound annual growth rate of Lyra Therapeutics Inc's revenue for the next 3 years is 115%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 268,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.